Supernus Pharmaceuticals IncSUPN
Price$42.18Intrinsic value$35.2117% below price

Valuation

How Intrinsic Value compares with model outputs

Intrinsic Value $35.21median of 3 methodsbased on filings through 30 Jun 2026
Market Price $42.18Price as of 1 Oct 2026
Margin of Safety -16.5%as of 1 Oct 2026

Valuation methods vs. Market Price

Company vs. peer median Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions

ParameterValue
Years 1–5: analyst growth pathFive-year total matches analyst consensus exactly. Year 1: 21.4% (near-term consensus, capped) · years 2–5: 18.0%/yr (balance of the path).18.6% per year
Years 6–10: glide to demonstrated growth
Per-year rates
Yr 618.1%Yr 718.2%Yr 818.4%Yr 918.5%Yr 1018.6%
18.0% → 18.6%
Years 11–20: glide to long-run rate
Per-year rates
Yr 1117.1%Yr 1215.5%Yr 1313.9%Yr 1412.4%Yr 1510.8%Yr 169.3%Yr 177.7%Yr 186.1%Yr 194.6%Yr 203.0%
18.6% → 3.0%
Beyond year 20: terminal growthPerpetual long-run rate3.0%
Discount rate (cost of equity) 8.1%
Volatility vs market (adjusted beta)0.70

Valuation Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions Sandbox Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Compare with peers

Search any company to compare valuation, profitability, returns, growth, and financial strength side by side.

Compare the target company plus 1 peer. Sign in / Sign up to compare a maximum of 3 peers.

Best in rowHigher is betterLower is better—Data not available
TargetSupernus Pharmaceuticals IncSUPNHealth Care
Valuation
P/E—
P/S3.0×
P/B2.4×
EV / Revenue2.8×
EV / EBITDA54.1×
Profitability
Gross margin88.7%
Operating margin-4.0%
Net margin-13.2%
FCF margin2.3%
Returns
ROE-10.7%
ROA-7.7%
ROIC—
Growth
Revenue growth (YoY)25.5%
5-yr fwd EPS growth18.6%
Financial strength
Debt / Equity0.00×
Current ratio2.08×
Altman Z-Score4.9
Interest coverage—
Dividend yield—

Best value in each row is highlighted. Figures are periodic snapshots from the same filings used across each dossier; a dash means the figure is not available.

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.